Abstract:Although oral delivery of insulin offers a number of unmatched advantages, it nevertheless is beset by the poor permeability of insulin molecules through the epithelial cell membranes of the intestinal mucosal layer. We previously reported the development of low molecular weight protamine (LMWP) as a non-toxic yet potent cell-penetrating peptide, of which via covalent linkage was capable of translocating protein cargos through the membranes of almost all cell types. It is therefore hypothesized that LMWP could be practically employed as a safe and effective tool to deliver insulin across the intestinal mucosal membrane, thereby augmenting its absorption through the GI tract. However, formulating 1:1 monomeric insulin/LMWP conjugate presents a tall order of challenge, as the acidic insulin and basic LMWP would automatically form tight aggregates through electrostatic interactions. In this paper, we developed an innovative conjugation strategy to solve this problem, by using succinimidyl-[(N-maleimidopropionamido)-polyethyleneglycol] ester (NHS-PEG-MAL) as an intermediate cross-linker during the coupling process. Both SDS–PAGE and MALDI–TOF mass spectroscopy confirmed the formation of a homogenous, monomeric (1:1 ratio) insulin/LMWP conjugate without encountering the conventional problem of substrate aggregation. Cell culture studies demonstrated that transport of the Insulin-PEG-LMWP conjugate across the intestinal mucosal monolayer was augmented by almost five-folds compared to native insulin. Furthermore, results from the in situ loop absorption tests in rats showed that systemic pharmacological bioavailability of insulin was significantly enhanced after its conjugation with LMWP. Overall, the presented chemical conjugation with LMWP could offer a reliable and safe means to improve the intestinal permeability of therapeutic peptides/proteins, shedding light of the possibility for their effective oral delivery.

Supramolecular Protein Engineering: DESIGN OF ZINC-STAPLED INSULIN HEXAMERS AS A LONG ACTING DEPOT

Insulin and Its Single-Chain Analogue

Supramolecular Approaches for Insulin Stabilization Without Prolonged Duration of Action

Supramolecular Assembly of Cp1-11 Peptide and Insulin for Rapid-Acting Formulation

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin

Improvement of protein loading and modulation of protein release from poly(lactide-co-glycolide) microspheres by complexation of proteins with polyanions.

Engineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic

Chemical synthesis of peptides within the insulin superfamily

Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues

The Use of Low Molecular Weight Protamine Chemical Chimera to Enhance Monomeric Insulin Intestinal Absorption

Surface Adsorption-Mediated Ultrahigh Efficient Peptide Encapsulation with a Precise Ratiometric Control for Type 1 and 2 Diabetic Therapy.

Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist

Clues to the Design of Aggregation-Resistant Insulin from Proline Scanning of Highly Amyloidogenic Peptides Derived from the N-Terminal Segment of the A-Chain

Single-Shot Solid-Phase Synthesis of Full-Length H2 Relaxin Disulfide Surrogates

Multiresponsive Supramolecular Theranostic Nanoplatform Based on Pillar[5]arene and Diphenylboronic Acid Derivatives for Integrated Glucose Sensing and Insulin Delivery

Tuning Insulin Receptor Signaling Using De Novo Designed Agonists

Efficient Encapsulation of Insulin by Giant Macrocycle as a Powerful Approach to the Inhibition of Its Fibrillation

A Co-Formulation of Supramolecularly Stabilized Insulin and Pramlintide Enhances Mealtime Glucagon Suppression in Diabetic Pigs.

Designing Insulin Analogues with Lower Binding Affinity to Insulin Receptor than That of Insulin Icodec

A structurally minimized yet fully active insulin based on cone-snail venom insulin principles

An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides